Two pharmaceutical companies half a year's performance rose a drop (figure)

Today, the Purple Medicine Industry (002118) and the state Pharmaceutical (002004) Two pharmaceutical companies published 2010.5 annual Report, the former net profit growth of 30% Year-on-year, the latter fell 24%. Purple Xin Pharmaceutical disclosed that in the first half of 2010, the company realized operating income of 113 million yuan, a year-on-year growth of 15.64%, to achieve the ownership of the listed company shareholders of the net profit of 26.22 million yuan, an increase of 30.09%.　　Company in ensuring the original prescription drug sales, and constantly strengthen the OTC market development, improve the OTC sales network, and into the third terminal sales, while the reporting period also opened up a new profit growth. Purple Xin Pharmaceutical industry specifically mentioned that the company set up in the reporting period of Jilin Zi Xin Yuan Pharmaceutical Co., Ltd., and Jilin Zi Xin Wisdom Pharmaceutical Co., Ltd. two wholly-owned subsidiaries, and to establish a new production base in Dunhua and Tonghua. At present, the company's four production base of the main business are ginseng deep processing and finishing products.　　Purple Xin Pharmaceutical said, strive in three years, the company's ginseng industry to reach 800 tons of processing capacity per year, solid company in the ginseng processing market position, the formation of Chinese patent medicine preparation, ginseng finishing and deep processing of two industrial main line. And on July 1, the purple Xin pharmaceutical industry has just announced its targeted additional plans. The company intends to publish not more than 90 million shares, raising funds of 1 billion yuan for Ginseng products serialization project.　　The company pointed out that after the completion of the project, the Sun ginseng, strong ginseng, molded red ginseng processing and sales business will be in the company's main business income accounted for a larger share of traditional Chinese medicine products are more abundant varieties, product structure will be a major change. In the first half of 2010, the company realized operating income of 259 million yuan, down 1.28% from a year earlier, and achieved net profit of 45.8 million yuan, down 24.18% from a year earlier, according to the semiannual pharmaceutical report. Company explained that the reporting period of the company's net profit decline is the main reason is that the first half of 2009, the company's subsidiaries Hua Bang Hotel transfer of 19.24 million yuan, and 2010 the same period in the company no more than the profits. It is deducted from the non-recurrent profit and loss, the company's main business to achieve net profit of 42.96 million yuan, compared with the same period in 2009 increased 4.07 million yuan, an increase of 10.46%.